Navigation Links
Companion Biomarkers in Drug Development - 2013 Examines Companies That Are Actively Developing and Marketing Companion Biomarkers
Date:11/22/2013

DUBLIN, November 22, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/6gr8mq/companion) has announced the addition of the "Companion Biomarkers in Drug Development" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)
Companion biomarkers are diagnostic tests that are specifically linked to a therapeutic drug either during its development or in the clinic. This linkage can be an important component of the drug development process; alternatively, the companion biomarker can be useful in ameliorating the regulatory process for the drug, or acting as an aid to therapeutic use in the clinic.

Market opportunities for companion biomarkers are focused in drug development targets, drug development efficacy and clinical end points in four main therapeutic areas: oncology, cardiovascular, neurology and autoimmune. Using companion biomarkers yields safer and more efficacious drug products, reduces clinical trial and development costs, improves post-marketing safety profiles and salvages therapies that otherwise would not be granted approval.

This report focuses on the role of companion diagnostic tests in drug development. It provides an in-depth discussion and analysis of the application of companion biomarkers to drug development and targeted therapeutics, as well as their use in clinical trials and the regulatory forum. The examination emphasizes new and developing technology platforms meant to aid in development of drugs for therapeutic use, and sometimes to be available as companion tests for these drugs in the clinic. Detailed tables and charts with sales forecasts and marketshare data are also included. 


Companies Mentioned:

- Abbott Laboratories
- Affymetrix
- Biomax Informatics
- Compugen
- Electric Genetics
- Eli Lilly and Company
- ePitope Informatics
- Fujitsu
- GlaxoSmithKline
- Hologic Gen-Probe
- IBM

- INCOGEN, Inc
- Ipsen
- Jerini AG
- Johnson & Johnson
- Koada Technology
- Luminex
- Merck & Co, Inc
- Novartis
- Oracle
- Oxonica
- PamGene BV
- Qiagen
- Randox Laboratories-
- Roche
- Silicon Genetics
- Thomson Reuters
- Ventana Medical Systems
- Wyeth
- Zeptosens



For more information visit http://www.researchandmarkets.com/research/6gr8mq/companion

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. QIAGEN Announces Third Co-Development Program for Companion Diagnostics Paired With Lillys Investigational Cancer Compounds
2. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
3. ResearchMoz: Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
4. Accelerating Drug Development Through Drug & Companion Diagnostic Co-development, New Life Science Webinar Hosted by Xtalks
5. Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests
6. MarketResearchReports.Biz: Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma And Others) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019 - New Industry Report
7. Companion Diagnostics Market is Expected to Reach USD 5.6 Billion Globally in 2019: Transparency Market Research
8. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
9. Life Technologies to Collaborate with Merck Serono for Companion Diagnostics Development and Commercialization
10. Medical Design Excellence Awards Selects Companion 2 Hospital Driver for Powering SynCardia Total Artificial Heart as Silver Winner
11. Empire Genomics Awarded SBIR Phase I Grant from NCI for Companion Diagnostics for Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
(Date:12/8/2016)... HOWELL, N.J. , Dec. 8, 2016 /PRNewswire/ ... aquatic augmentation remediation technologies and selected NewTechBio,s NT-MAX ... , a microbial based beneficial bacteria, in conjunction ... Inc., to correct deficiencies with National Pollutant Discharge ... basin 281-8H has experienced a steady history of ...
(Date:12/8/2016)... 2016  Partnering to fuel Philadelphia,s ... of Southeastern Pennsylvania (" Ben ... of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... a $6 million funding initiative over a four year ... Responding to a burgeoning economic vitality in digital health, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... phase I/II dose escalation and expansion clinical trial for its lead drug candidate, ... The purpose of the trial was to determine the safety, antitumor activity, and ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):